HTG Therapeutics is focused on utilizing its innovative technology platforms to create an entirely new generation of drug discovery tools aimed at developing therapeutic candidates with superior efficacy and safety profiles - transforming the process across a broad range of disease areas including oncology, immunology, diabetes, and rare diseases, among others.
HTG EdgeSeq and Epi-EdgeSeq technology enables a more highly resolved view of the transcriptome, especially aberrations in the physiological states leading to disease. By assimilating sophisticated RNA profiling and advanced medical chemistry technologies directly - and early-on - in the process, researchers can access critical learnings much sooner, significantly reduce risk, and increase successful outcomes.
On July 27, 2022 HTG hosted a key opinion leader (KOL) webinar on “Drug Candidate Attrition – How to Improve Clinical Development Success and Patient Outcomes”.
The webinar featured a presentation from KOL, Dr. Robert Spitale, PhD, University of California – Irvine, who discussed the use of RNA-based platform technologies in drug discovery. The HTG Therapeutics team introduced their proprietary transcriptome-informed drug discovery platform as the cornerstone of their differentiated and de-risked approach to small molecule drug discovery.
HTG Therapeutics leverages its transcriptomic and epi-transcriptomic profiling technology to dramatically transform the drug discovery process. HTG's platform currently produces a profile with nearly 42,000 data points per sample in three independent data sets and has the ability to detect changes in RNA modifiations, such as N6-methyladenosine (m6A), which has been increasingly implicated in various disease states.
By leveraging HTG's unique profiling technologies earlier in the drug discovery process, HTG Therapeutics is expected to generate lead compounds faster, and with superior efficacy and toxicity profiles.
HTG Therapeutics will identify development candidates targeting RNA and RNA-modifying proteins, targets relevant in a wide range of diseases of unmet therapeutic need. The profiling of these diseases using the HTG EdgeSeq technology is an essential element in guiding these efforts. From hit to lead clinical candidate- HTG seeks to bring to the forefront the power of transcriptome profiling and data science to generate insights factoring into the selection of improved therapeutic candidates entering clinical trials.
Page last updated July 29, 2022